/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Eloxx Pharmaceuticals Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$2.86 -0.0568(-5.68%) ELOX at 04 Dec 2025 04:30 PM Biotechnology
Lowest Today 3.79
Highest Today 4.29
Today’s Open 4.11
Prev. Close 4.05
52 Week High 10.90
52 Week Low 1.70
Day’s Range: Low 3.79 High 4.29
52-Week Range: Low 1.70 High 10.90
1 day return -
1 Week return -
1 month return -
3 month return -
6 month return -
1 year return -
3 year return -
5 year return -
10 year return -

Institutional Holdings

SILVERARC CAPITAL MANAGEMENT, LLC 1.96

MENORA MIVTACHIM HOLDINGS LIMITED 1.90

American Financial Group Inc 1.34

Altshuler Shaham Ltd 0.91

Vanguard Group Inc 0.75

Geode Capital Management, LLC 0.74

Vanguard Institutional Extnd Mkt Idx Tr 0.72

Clal Insurance Enterprises Holdings Ltd 0.53

BlackRock Inc 0.32

Fidelity® Extended Market Index 0.32

BlackRock Extended Mkt Composite 0.27

BlackRock Extended Equity Market K 0.24

Fidelity® NASDAQ Composite Index® 0.11

Fidelity® Total Market Index 0.10

Tower Research Capital LLC 0.09

NT Ext Equity Mkt Idx Fd - NL 0.06

Fidelity® Series Total Market Index 0.06

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.05

Northern Trust Extended Eq Market Idx 0.04

NT Ext Equity Mkt Idx Fd - L 0.04

Wells Fargo & Co 0.04

iShares Core S&P Total US Stock Mkt ETF 0.04

Vanguard U.S. Eq Idx £ Acc 0.03

Royal Bank of Canada 0.03

Extended Equity Market Fund M 0.03

Spartan Total Market Index Pool E 0.03

Spartan Extended Market Index Pool E 0.02

SSgA U.S. Extended Market Index Class I 0.01

State St US Extended Mkt Indx NL Cl C 0.01

NT Quality SCC US Fund - L 0.00

NT Quality Small Cap Core 0.00

Morgan Stanley - Brokerage Accounts 0.00

Meeder Asset Management Inc 0.00

Group One Trading, LP 0.00

Bank of America Corp 0.00

Harel Insurance Invests & Fin Srvcs Ltd 0.00

JPMorgan Chase & Co 0.00

NewSquare Capital, LLC 0.00

UBS Group AG 0.00

Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 14.86 M

PB Ratio 6.3127

PE Ratio 0.0

Enterprise Value 30.28 M

Total Assets 21.12 M

Volume 92763

Company Financials

Annual Revenue FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M, FY18:0 0.0M

Annual Profit FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M, FY18:0 0.0M

Annual Net worth FY22:-36113000 -36.1M, FY21:-65767000 -65.8M, FY20:-38024000 -38.0M, FY19:-50315000 -50.3M, FY18:-47185000 -47.2M

Quarterly Revenue Q2/2023:0 0.0M, Q1/2023:0 0.0M, Q4/2022:0 0.0M, Q3/2022:0 0.0M, Q2/2022:0 0.0M

Quarterly Profit Q2/2023:null 0.0M, Q1/2023:null 0.0M, Q4/2022:null 0.0M, Q3/2022:null 0.0M, Q2/2022:null 0.0M

Quarterly Net worth Q2/2023:-4341000 -4.3M, Q1/2023:-6977000 -7.0M, Q4/2022:-6247000 -6.2M, Q3/2022:-7493000 -7.5M, Q2/2022:-10476000 -10.5M

Fund house & investment objective

Company Information Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

Organisation Biotechnology

Employees 18

Industry Biotechnology

CEO Mr. Sumit Aggarwal M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow